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Abstract
Introduction  and  objectives:  Papillary renal cell carcinoma (PRCC) accounts for 10–15% of renal tumors in
adults. This type of tumor contains more than 75% of tubulo-papillary structures and is divided histologically
into two subtypes. The distinction between these two subtypes is essential because of their prognostic value.
The aim of this study was to compare the prognostic significance of the PRCC subtypes.
Patients  and  methods:  This retrospective study included 34 patients operated for PRCC between January
2000 and December 2012. Clinical data including presenting symptoms, preoperative findings, pathological
features, treatment and patient outcome were taken from the patients’ medical records as well as from
radiological analysis based on computed tomography (CT) findings. A second analysis of the histological
slides was made in doubtful cases to clarify the histological subtype.
Results:  PRCC was found in 12.7% of 267 patients operated for renal tumors during the study period. The
patients’ mean age was 62.4 years with a male predominance (sex ratio 3.6). All tumors were unilateral
with a mean size of 6.9 cm. There was no clinical or radiological sign suggestive of this histological type,
however, 80% of the tumors had an enhancement <40 HU. Treatment consisted of radical nephrectomy and
nephron-sparing surgery in 74% and 26% of the cases, respectively. We found 20 type-1 tumors and 14
rall and disease-free survival rates were 82% and 90% for type-1 and 42%
spectively.type-2 tumors. The 5-year ove
and 54% for type-2 tumors, re∗ Corresponding author.
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Conclusion:  PRCC represents the second most common histological type of renal cancer. It has no clinical
or radiological predicting signs, although CT enhancement is usually <40 HU. Distinguishing between the
two subtypes is essential because of their prognostic value.
© 2016 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. All rights reserved.
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apillary renal cell carcinoma (PRCC) accounts for 10–15% of renal
umors in adults. This type of tumor contains more than 75% of
ubulo-papillary structures [1]. PRCC represents the second most
ommon histological type after clear cell carcinoma (CCC). In 1997,
elahunt and Eble [2] described type-1 and type-2 subtypes of
RCC according to their cytological characteristics. This subdivi-
ion is important because of the prognostic value of each subtype
1–5].
n the present study covering a period of 13 years, we reviewed 34
ases of PRCC operated between January 2000 and December 2012
nd performed a long-term survival analysis comparing type-1 and
ype-2 PRCC to validate this subclassification as a prognostic factor.
atients  and  methods
uring the study period, 34/267 patients (12.7%) operated for renal
ancer at our institution were diagnosed with PRCC. Data were
btained from the patients’ medical records. The presenting symp-
oms, preoperative findings, pathological features, treatment and
atient outcome were analyzed, and a comparative study of type-1
nd type-2 PRCC was carried out.
he tumor stage was determined according to the 2009 TNM clas-
ification. A second analysis of the histological slides was made in
oubtful cases to clarify the histological subtype. The tumor was
lassified as type-1 PRCC when it showed papillae covered with a
ingle or double layer of small cuboid cells with basophilic cyto-
lasm (Fig. 1). Type-2 PRCC contains papillae covered with large
osinophilic cells arranged in a pseudo stratified manner (Fig. 2).
igure  1  Type 1 PRCC tumors showing papillae covered with small
uboid cells with basophilic cytoplasm.
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4igure  2  Type 2 PRCC tumors containing papillae covered with large
osinophilic cells arranged in a pseudo stratified manner.
he statistical tests used were the Chi-square test to compare the
ualitative variables and student’s t-test for continuous variables,
hile the survival curves were derived from Kaplan–Meier esti-
ates. A log-rank test was used to compare the survival rates of both
roups. A p  value <0.05 was considered as statistically significant.
he statistical analysis was carried out using the SPSS 10.0 program.
esults
RCC was found in 34/267 patients (12.7%) that underwent surgery
or renal cancer. It represented the second most common histological
ype after CCC (75%). The patient cohort consisted of 25 men (74%)
nd 7 women (26%) with a sex ratio of 3.6. The patients’ mean age
as 62.4 (range 24–86) years.
he main risk factors were hypertension and diabetes mellitus, noted
n 32% and 18%, respectively. Hemodialysis for end-stage renal
isease was found in one case (3%).
he main presenting symptoms were flank pain (n  = 22) and hema-
uria (n  = 12). The tumor was discovered incidentally in 9 patients
27%). Most incidental cases were diagnosed after the second half
f the study period (8% before 2005 and 44% after that year).
he tumors were located in the right kidney in 52% and in the
eft kidney in 48% of the patients. All tumors were unilateral, and
ultifocality was noted in one case (3%). The median tumor size
as 6.9 cm (range 1.9–24) cm.
omputer tomography (CT) did not show any specificity regarding
his histological type, however, enhancement was low (less than
0 HU) in 80% of the cases.
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Table  1  Comparison between Type 1 and Type 2 PRCC tumors.
Type 1 Type 2 P value
Patients (n) 20 14
Mean age (yr) 64.8 63.7 NS
Male/female 15/4 11/3 NS
Incidental diagnosis (%) 6/20 (30) 3/14 (21) NS
Median tumor size (cm) 6.6 8.5 NS
Range 3–20 1.9–24
Nephron sparing surgery (%) 6/20 (30) 3/14 (21) NS
TNM classification (%)
pT1 T2 N0 M0 17 (85) 6 (43) <0.005
pT3 T4 N1 M0 3 (15) 8 (57)
Fuhrman grade (%)
Low (1.2) 15 (75) 4 (28) <0.005
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NS, not significant.
Radical nephrectomy was performed in 25 cases (74%), while 9
patients (26%) were subjected to partial nephrectomy. Only open
partial nephrectomies with vascular clamping were performed at
our institution. The mean warm ischemia time was 30 (range 20–45)
min.
Immediate complications occurred in 5 patients (18%): urinary fis-
tula in one, pulmonary embolism in one and wound infection in 3
patients. Internal drainage by ureteral stenting was needed for the
treatment of urinary fistula. Blood loss was negligible in all but two
cases that needed blood transfusion. Nephron-sparing surgery was
noted to be associated with a higher morbidity. The mean hospital
stay was 5 (range 3–30) days.
Histological studies showed a tubulo-papillary aspect in 63% of the
cases, while a pure papillary aspect was seen in 37%. The presence
of sarcomatoid cells was noted in one case.
We found 20 cases of type-1 (59%) and 14 cases of type-2 PRCC
(41%). Immunohistochemical study was necessary in one case to
confirm the histologic diagnosis. It showed cells positive for cyto-
keratin 7.
The median follow-up after surgery was 42 (range 6–100) months.
The 5-year overall survival and disease-free survival rates were
73.3% and 92%, respectively. Recurrence occurred in 3 cases two
years after surgery; none of them had had partial nephrectomy as
initial treatment.
The tumor characteristics according to the pathologic subtype are
summarized in Table 1. Type-2 tumors were associated with a more
advanced TNM stage, a high Fuhrman grade (grades 3 and 4) and
a worse prognosis. The overall and disease-free survival rates were
82% and 90% for patients with type-1 tumors and 42% and 54% for
those with type-2 tumors, respectively. The Kaplan–Meier overall
survival is presented in Fig. 3.
Discussion
PRCC derives from cells of the distal tubule of the nephron [1]. This
type of tumor represents the second most common histological type
of renal cancer after CCC, accounting for 10–5% of the cases. It
is usually diagnosed between the age of 50 and 60 [6] and occurs
more frequently in men with a sex ratio of 1.6–5.
a
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tigure  3  The Kaplan–Meier overall survival curves according to
umor subtype.
he most common risk factors for renal cancer are hypertension,
iabetes mellitus, obesity and smoking [7,8]. End-stage renal failure
s a well-known risk factor of PRCC [9,10], but this was not found in
ur study. The male predominance (3/4 of our patients with PRCC)
oted in this study confirms the results of previous studies [1].
ccording to the literature, renal cancer is diagnosed incidentally
n 60–70% of cases [7]; however in our study, incidental diagnosis
as not common (29%) because we lack ultrasonography in rural
ospitals.
ultifocality is another known feature of PRCC, with a reported
ncidence of 20% to 41% [2], however, this high percentage is usu-
lly found in hereditary cases [11]. Cytogenetic studies suggest that
any mutations in different locations of the same kidney explain
ultifocality in hereditary PRCC [12]. In sporadic cases, multifo-
ality of PRCC has been reported to account for around 7% [1,5].
n our study, we did not find any association between multifocality
nd PRCC as all cases were sporadic.
T scan is the gold standard for exploring renal tumors. PRCC is
sually more homogenous than CCC, especially in tumors <3 cm
ith less enhancement [13,14]. These findings are usually correlated
o low-stage tumors [4]. There are no radiological signs that can
istinguish between the two PRCC subtypes. In this study we found
hat 80% of the tumors had an enhancement < 40 HU.
he histological pattern shows that PRCC is characterized by a pre-
ominance (more than 50–70%) of papillary or tubulo-papillary
tructures in the absence of clear cells [9]. In doubtful cases we can
se immunohistochemical studies to search for a positive reaction
o cytokeratin 7. Delahunt and Eble [2] were the first to describe
he existence of two PRCC subtypes. This subclassification was
dded to the WHO classification of 2004 [15]. Tumors are classi-
ed as type-1 PRCC when they show papillae covered with small
uboid cells with basophilic cytoplasm, whereas type-2 tumors con-
ain papillae covered with large eosinophilic cells. The latter are
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sually associated with a high TNM grade and a worse progno-
is. This prognostic value was confirmed by other studies, where a
isease-free survival rate of 92% was reported for type-1 compared
o 44% for type-2 PRCC tumors [1,16].
onclusions
RCC represents the second most common histological type of renal
ancer. It has no clinical or radiological predicting signs, although
T enhancement is usually less than 40 HU. Distinguishing between
ts two subtypes is essential because of their prognostic value.
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